News

Le Lézard1d
Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR | MarketsandMarketstm
The global Biomarkers Market, valued at US$58.07 billion in 2024 stood at US$62.39 billion in 2025 and is projected to advance at a resilient CAGR of 10.8% from 2025 to 2030, culminating in a ...
Yahoo Finance6mon
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
1,2 The VENTANA FOLR-1 (FOLR1-2.1) test informs clinicians about the likelihood of potential patient benefit from FOLR1 therapy, 3,4 advancing Roche's commitment to personalised healthcare through ...
Yahoo Finance6mon
Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
1,2 The VENTANA FOLR-1 (FOLR1-2.1) test informs clinicians about the likelihood of potential patient benefit from FOLR1 therapy, 3,4 advancing Roche's commitment to personalised healthcare through ...
Pharmabiz11mon
Roche introduces VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, a new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
Roche announced the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting ...
Seeking Alpha2y
Roche receives FDA approval for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERE
TUCSON, Ariz., Nov. 14, 2022 /PRNewswire/ -- Roche (RHHBY) today announced US Food and Drug Administration (FDA) approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first ...
Business Insider2y
Roche's VENTANA PD-L1 (SP263) Assay receives CE IVD approval to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo
TUCSON, Ariz., Sept. 9, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the VENTANA PD-L1 (SP263) Assay is available in countries accepting the CE mark as a companion ...
KXAN2y
Roche's VENTANA PD-L1 (SP263) test gains CE label expansion as a companion diagnostic to identify non-small cell lung cancer patients eligible for Tecentriq
The VENTANA PD-L1 (SP263) Assay was used in the IMpower010 study sponsored by Genentech, a member of the Roche Group, to identify patients whose tumours expressed the PD-L1 protein. The IMpower010 ...
Stockhouse2y
Roche receives FDA approval for VENTANA MMR RxDx Panel to identify dMMR solid tumour patients and pMMR endometrial cancer patients eligible for KEYTRUDA
TUCSON, Ariz., Aug. 11, 2022 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of a label expansion for the VENTANA MMR RxDx Panel. This ...
Yahoo Finance2y
Roche launches the VENTANA DP 600 slide scanner for digital pathology, enhancing patient care with precision diagnostics
The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment.
Yahoo Finance3y
Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq ...
Lung cancer remains the leading cause of cancer-related deaths worldwide, with more than 2.2 million people diagnosed globally last year. 1 The VENTANA PD-L1 (SP263) Assay helps determine which ...
Mena FN4y
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
March 9, 2021 /PRNewswire/ -- Roche (SIX: RO, ROG;OTCQX:RHHBY ) today announced US Food and Drug Administration (FDA) approval of the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to ...